Company Valuation: Concord Biotech Limited

Data adjusted to current consolidation scope
Fiscal Period: March 2024 2025 2026 2027 2028
Capitalization 1 1,59,100 1,75,818 1,41,336 - -
Change - 10.51% -19.61% - -
Enterprise Value (EV) 1 1,58,709 1,72,645 1,37,506 1,36,207 1,34,172
Change - 8.78% -20.35% -0.94% -1.49%
P/E ratio 51.6x 47.3x 40.1x 31.8x 25.3x
PBR 10.4x 9.7x 6.79x 5.8x 4.89x
PEG 1.8x 2.3x -7.97x 1.2x 1x
Capitalization / Revenue 15.6x 14.7x 11.2x 9.03x 7.63x
EV / Revenue 15.6x 14.4x 10.9x 8.7x 7.24x
EV / EBITDA 36.8x 34.1x 28x 21.8x 17.8x
EV / EBIT 42x 38.2x 31.7x 23.8x 18.9x
EV / FCF 88.3x 129x 48.8x 39.4x 30.6x
FCF Yield 1.13% 0.77% 2.05% 2.54% 3.27%
Dividend per Share 2 8.75 10.7 11.85 13.93 16.1
Rate of return 0.58% 0.64% 0.88% 1.03% 1.19%
EPS 2 29.45 35.52 33.73 42.52 53.44
Distribution rate 29.7% 30.1% 35.1% 32.8% 30.1%
Net sales 1 10,169 12,001 12,632 15,656 18,523
EBITDA 1 4,316 5,063 4,905 6,240 7,520
EBIT 1 3,780 4,520 4,331 5,715 7,094
Net income 1 3,081 3,716 3,617 4,570 5,715
Net Debt 1 -391.7 -3,173 -3,831 -5,130 -7,165
Reference price 2 1,520.80 1,680.60 1,351.00 1,351.00 1,351.00
Nbr of stocks (in thousands) 1,04,616 1,04,616 1,04,616 - -
Announcement Date 24/05/24 29/05/25 - - -
1INR in Million2INR
Estimates

P/E ratio, Detailed evolution

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
40.05x10.89x28.03x0.88% 156.44Cr
18.17x4.9x12.43x0.49% 7.61TCr
59.2x15.67x33.6x-.--% 6.2TCr
43.53x6.83x22.35x0.54% 5.72TCr
22.49x4.1x11.91x2.63% 5.67TCr
16.24x2.69x8.48x-.--% 2.47TCr
16.99x3.35x10.06x-.--% 2.07TCr
81.48x9.75x87.9x-.--% 1.98TCr
346.83x105.22x170.97x - 1.71TCr
-4.88x5.4x-3.18x-.--% 1.54TCr
Average 64.01x 16.88x 38.26x 0.5% 3.51TCr
Weighted average by Cap. 48.72x 11.95x 28.66x 0.66%
See all sector valuations

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

Year-on-year evolution of the Yield

  1. Stock Market
  2. Equities
  3. CONCORDBIO Stock
  4. Valuation Concord Biotech Limited